Finding new treatments for lung squamous cell carcinoma by targeting a specific protein
High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation Reader
This study is looking at a protein called YEATS2 that is often found in high levels in lung squamous cell carcinoma, a type of lung cancer, and aims to find new drugs that can block this protein to help improve treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Van Andel Research Institute NIH-funded |
| Lab location | 1 site (Grand Rapids, United States) |
| Project ID | NIH-11004261 on NIH RePORTER |
What this research studies
This research focuses on lung squamous cell carcinoma (LUSC), a type of lung cancer with limited treatment options. The team is investigating the YEATS2 protein, which is often found in higher amounts in LUSC and is linked to poor patient outcomes. By screening a large library of chemicals, they aim to identify inhibitors that can block the activity of YEATS2, potentially leading to new therapeutic strategies. The approach involves advanced techniques to assess how these inhibitors affect cancer cell growth and survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung squamous cell carcinoma or other cancers associated with high YEATS2 expression.
Not a fit: Patients with cancers not related to YEATS2 or those without lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for patients with lung squamous cell carcinoma.
How similar studies have performed: Previous research has shown promise in targeting similar proteins in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Grand Rapids, United States
- Van Andel Research Institute — Grand Rapids, United States (Active)
Researchers
- Principal investigator: Shi, Xiaobing — Van Andel Research Institute
- Study coordinator: Shi, Xiaobing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.